Dr. James LaBelle, Former Chief Medical Officer of Scripps Health, Joins Eyam Vaccines and Immunotherapeutics Board of Directors
Back to Newsroom
Mentioned in this Article

Dr. James LaBelle, Former Chief Medical Officer of Scripps Health, Joins Eyam Vaccines and Immunotherapeutics Board of Directors

Thursday, January 14, 2021 9:00 AM
Share this article now
Company Update

VANCOUVER, BC / ACCESSWIRE / January 14, 2021 / Eyam Vaccines and Immunotherapeutics (EYAM) today announced that Dr. James LaBelle, Chief Medical Officer of Ripplenami, joined EYAM's board of directors.

Dr. LaBelle, a physician executive with more than 20 years' experience as a patient-focused physician leader, has built impressive sustainable clinical and financial improvement systems over his career, with an emphasis on supporting clinician wellness and cultural health.

As Ripplenami's Chief Medical Officer, Dr. LaBelle develops and implements strategies supporting Ripplenami's African business partners use of proprietary technologies in health management applications including COVID-19.

"Dr. LaBelle's broad interest and expertise in using technology to enable affordable healthcare with consistent, high quality outcomes is an excellent match with EYAM's vision for vaccine research and development," EYAM's CEO, Ryan Thomas said.

As Scripps Health Senior Vice President and Chief Medical Officer in LaJolla, California, Dr. LaBelle's responsibilities included a 5 hospital regional healthcare system in San Diego with 2600 physicians and three billion dollars in annual revenue.

In 1999, Dr. LaBelle earned his Healthcare Executive Masters of Business Administration from the University of California at Irvine. In 2010 he received his Board Certification in Medical Management from the American College of Physician Executives.

Dr. LaBelle attended medical school at the University of Washington and completed his Residency in Internal Medicine at the University of California at San Diego. Dr. LaBelle also holds a Bachelors of Science Degree in Electrical Engineering.

The news is significant for EYAM as 3 COVID-19 vaccine candidates transition into animal trials.

About Eyam Vaccines and Immunotherapeutics: Eyam Vaccines and Immunotherapeutics is a private, Canadian based company focused on the research and development of vaccines that are safe, efficacious and low dose. Eyam, was named to honour the village in Derbyshire that, in 1665-1666, chose to stay and brave near certain death rather than travelling and risk transmitting the plague to their neighbouring towns. In the end, 75% of Eyam's residents did indeed die, but their surrounding neighbours were saved due to Eyam's heroic and selfless quarantine. For further information see: https://royalsocietypublishing.org/doi/10.1098/rspb.2016.0618.

For further information:

Website: eyamhealth.com
Email: [email protected]

SOURCE: Eyam Vaccines and Immunotherapeutics

Eyam Vaccines and Immunotherapeutics
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: